

MARK D. SORRENTINO M.D., M.S.
19630 Hoover Farm Dr.
Laytonsville, Maryland 20882
301-216-2214 (home) 301-526-4372 (mobile)
E-Mail: sorrentinom@comcast.net

EDUCATION:

UNIVERSITY OF HEALTH SCIENCES/THE CHICAGO MEDICAL SCHOOL,

North Chicago, Illinois

M.D. awarded May 1994

M.S. in Clinical Nutrition awarded May 1994.

Scholastic Testing: NBME Part I – 191
NBME Part II – passed
NBME Part III- passed

LOS ANGELES PIERCE COLLEGE OF NURSING

Woodland Hills, California

A.A./R.N. in Nursing awarded June 1989. Dean's List: 1988-1989

LOYOLA MARYMONT UNIVERSITY

Los Angeles, California

B.S. in Biology awarded May 1987

MEDICAL TRAINING:

- Fellow, Critical Care Medicine, Children's National Medical Center, Washington D.C.; 1997 – 2001
- Resident Physician, Pediatrics, Children's National Medical Center, Washington D.C.; 1994 – 1997
- Pediatric Advanced Life Support Instructor; 1994 – present
- Medical License #21694, Washington D.C.; 1996-current
- Medical License #D0060828, Maryland. Exp. 2003-current
- Board Eligible: Pediatric Critical Care & General Pediatrics

WORK EXPERIENCE

H.A.S. PHYSICIANS

Founder and Chief Medical Officer

- Personal healthcare advocacy

SOUTHERN MARYLAND HOSPITAL

Medical Director, Chief Medical Officer

3/03- 5/04

- Administrator of medical side of a 360-bed full-service community hospital
- 35 physician direct reports
- 450 community physicians on staff

CHILDREN'S NATIONAL MEDICAL CENTER Washington, DC

- Attending Pediatric Intensivist (part-time), Children's National Medical Center, Washington D.C.; 2001- present
- Clinical Assistant Professor, George Washington University School of Medicine; 2001-present
- Critical Care Transport Physician; 1995 – present

CUBIST PHARMACEUTICALS, Inc.

Medical Affairs Consultant

Current

GENESIS BIO-PHARMACEUTICALS, Inc.

Medical Affairs Consultant

Current

DRUG SAFETY SOLUTIONS

Safety Officer- 1/2003- 3/2003

- Performing duties of an outsourced Medical Safety Officer for a large biotech corporation

BIOSYNEXUS, Inc.

Senior Director, Clinical Trials- 6/2002-12/2002

- Overseeing/directing all aspects of a Phase I/II and a Phase II program related to neonatal sepsis including:
 - Protocol development and implementation
 - Choosing and evaluating potential investigators
 - Work with site Contracts Office and negotiate all aspects of the study contracts
 - Organize and plan investigators meetings
 - Drafting of statistical analysis plans
 - Managing in house Research Associates
 - Direct/manage all interaction with the Contract Research Organizations
 - Plan/prepare all DSMB meetings

- Participate as a member of the in-house Safety Monitoring Committee
- Direct all regulatory activities related to the studies
- Review all MedWatches and other safety information
- Draft all letters that are sent to the FDA
- Visit with site staff and primary investigators on a regular basis
- Competitive Intelligence
 - Monitor the internet and the medical literature for news in the area of sepsis/nosocomial infection
- Corporate Medical Safety Officer
 - Oversee the implementation of OSHA standards as they relate to health in the workplace
 - Organize Hepatitis B and Influenza vaccine programs

MEDIMMUNE, Inc.

Director Medical Sciences –6/98-6/2002

- Managed all aspects of >20 Phase IV/V projects including a 5000 patient RSV Registry with >100 sites. This included protocol development, site initiation visits, investigator’s meetings, CRO management, safety monitoring, analysis planning, publication writing and submission.
- Established and maintained relationships with key thought leaders in the areas of pediatric infectious diseases, neonatal medicine, and transplant medicine.
- Lectured on RSV and CMV across the country to physicians, nurses, insurance providers.
- Developed sales aids with medical data incorporated.
- Member of sales training team, and developed many sales training aids/presentations.
- Organized and managed two key physician advisory boards that met annually.
 - Kidney/Pancreas Advisory Board; Chair: John Pirsch M.D., University of Wisconsin
 - Midwest Neonatal Advisory Board; Co-Chairs: Av Fanaroff M.D., Rainbow Babies, and Jean Steichen M.D., University of Cincinnati

THE SCIENCE ADVISORY BOARD

Charter Member, Scientific Steering Committee; 2001- 2002

- Participated in directing the activities of the Board
- Wrote medical review articles for the Board’s website (www.scienceboard.net)
- Keynote speaker 5.21.02 at Board’s membership dinner

ILLINOIS MASONIC MEDICAL CENTER, Chicago, Illinois
Registered Nurse, Pediatric Intensive Care Unit, 1992-94

CHICAGO MEDICAL SCHOOL, Chicago, Illinois
CPR Instructor, 1992-1994

CHICAGO MEDICAL SCHOOL, Chicago, Illinois
Tutor: Physiology Department, 1990-91

HIGHLAND PARK HOSPITAL, Highland Park, Illinois
Registered Nurse, Adult Intensive Care Unit
1990 – 1991

**LOS ANGELES COUNTY – UNIVERSITY OF SOUTHERN CALIFORNIA
MEDICAL CENTER**, Los Angeles, California
Registered Nurse, Pediatric Intensive Care Unit, 1989-90

CORPORATE PUBLICATIONS:

Editor/Contributor: Southern Maryland Hospital physician newsletter (Medi-Scene),
2003-2004

Editor: Medical Affairs Bulletins, 1998-2002

Editor: Synagis™ Annotated Package Insert; June 1998

Editor: Synagis™ Training Modules; July 1998

Author: Risk Factors for CMV sales aid, April 1999

PUBLICATIONS:

B. Katz, J. Lo, **M. Sorrentino**. Costs of Respiratory Syncytial Virus Infection at a Tertiary-Care Children's Hospital. Pharmacy & Therapeutics. Vol.28, #5. May 2003.

The Synagis Outcomes Registry Study Group (**author/member**). Palivizumab Prophylaxis of RSV Disease in 2000-2001- Results from the Palivizumab Outcomes Registry. Pediatric Pulmonology 2003; 35:484-489.

S. Leader, P. Jacobson, J. Marcin, R. Vardis, **M. Sorrentino**, D. Murray. A Method for Identifying the Financial Burden of Hospitalized Infants on Families. Value in Health 2002. Vol.5, No.1:55-59.

A. Cohen, **M. Sorrentino**, T. Powers et al. Effectiveness of Palivizumab for Preventing Serious RSV Disease. The Journal of Respiratory Diseases, Nov. 2000. Vol.2, No.4 Supplement.

M. Sorrentino, T. Powers, the Palivizumab Outcomes Study Group. Effectiveness of Synagis® (Palivizumab): Evaluation of Outcomes from the 1998-99 RSV Season. The Pediatric Infectious Disease Journal 2000; 19:1068-1071.

ABSTRACTS

E.M. Connor, J.B. McClain, **M. Sorrentino** et al. Safety Surveillance in Children Treated with Palivizumab. Poster #33, AAP-NCE, Boston, 10/19/02.

B. McClain, **M. Sorrentino**. Safety in Infants Receiving More Than Five Doses of Palivizumab for RSV Prophylaxis. Poster Presentation. National Perinatal Association Annual Meeting, San Antonio, Nov. 2001.

M. Sorrentino, D. Charsha-May, et al. Severity of RSV LRI Hospitalizations in 33-35 Week and >36 Week Gestational Age Infants. Poster Presentation, APS/SPR, April 2001.

M. Sorrentino, T.Powers, and the RSV Outcomes Study Group. Multicenter Outcomes Following Synagis (Palivizumab) Humanized Monoclonal Antibody Administration for Protection from RSV Lower Respiratory Tract Infection: A Preliminary Analysis. Poster Presentation, National Perinatal Association annual meeting, Charlotte, NC, October 2000.

B.Z. Katz, J. Lo, **M. Sorrentino**. Costs of RSV at a Tertiary-Care Children's Hospital. Poster Presentation: Society of Pediatric Research, May 2000.

A.Cohen, RL Hirsch, **M. Sorrentino** et al, "First Year Experience Using Palivizumab Humanized Monoclonal Antibody for Protection from RSV Lower Respiratory Tract Infection." Oral presentation: Second World Congress of Pediatric Infectious Diseases, Nov. 2-6, 1999.

M. Sorrentino, A. Cohen, RL Hirsch et al, Protection from RSV Lower Respiratory Tract Infection: A First Year Experience Using Palivizumab Humanized Monoclonal Antibody. Oral presentation: Western Regional Society of Pediatric Research meeting, 2/20/2000.

Sorrentino M, Harpenau J, Scheck, S. Changes in Metabolic Rates During Short-term Cold Exposure on mus musculus. Department of Physiology, Loyola Marymount University, at the West Coast Undergraduate Biological Sciences Conference, 1987, oral presentation

BOOK CHAPTERS:

Sorrentino, M. Infectious Disease & Nutrition
In: Slonim, A.D. and Pollack, M.M; Pediatric Critical Care Board Review
Medtext Publishing, Redondo Beach, 2004.

Sorrentino, M and Slonim AD: Infectious Diseases in Pediatric Critical Care In: Intensive Thinking: Pediatric Critical Care 3rd Edition Hasan RA, Pappas MD, and Slonim AD, Eds. Medical College of Ohio Press 2001.

Marino et al: Blueprints in Pediatrics, 2001. In Press. Medical Content Reviewer.

Mustafa Hammad: Blackwell's Medical Intern Survival Guide, 9/2001. Medical Content Reviewer.

RESEARCH EXPERTISE:

“Non-medical Costs Borne by Caregivers of Infants Hospitalized with RSV in 2000-2001” Multi-center study, primary investigators, Shelah Leader, PhD, Mark Sorrentino, MD, MS

“The Impact of CytoGam® on the Time to Viral Load Reduction in Kidney or Pancreas Transplant Recipients with Clinical CMV Disease” John Pirsch, MD, University of Wisconsin, Mark Sorrentino, MD

“CMV in +/- Heart Transplantation” Thomas Waid, MD, University of Kentucky, Mark Sorrentino MD

“Correlation of Reinfections in Lung Transplant Patients with Hypogammaglobulinemia Receiving CytoGam®” Janet Maurer, MD, Cleveland Clinic Foundation, Mark Sorrentino MD

“Potential role for CytoGam® IVIG in Reducing Anti-HLA Antibodies in Allosensitized Patients” Ronald Pelletier, MD, Ohio State University Research Foundation, Mark Sorrentino, M.D.

“Efficacy of CMV Specific Immunoglobulin Titers in Preventing Viral Replication in Solid Organ Transplant recipients” Upton Allen, MD, Royal Victoria Hospital, Mark Sorrentino, M.D.

“The Impact of IgG Level Monitoring and CytoGam® Administration on the Clinical Outcome Following Cardiac Transplant” Mohamad Yamani, MD, the Cleveland Clinic Foundation, Mark Sorrentino, M.D.

“Cytokine Dysregulation, Viruses and Childhood Asthma”, Robert Lemanske, Jr., MD, University of Wisconsin

“Post-transplant Lymphoproliferative Disease: A Randomized Trial of Ganciclovir and Immune Globulin Prophylaxis in Solid Organ Transplant Recipients”, Upton Allen, MD, Hospital for Sick Children, Mark Sorrentino, M.D.

“Comparative Study of Immune & Clinical Response of Infants receiving High dose Titer RSV Immunoglobulin prophylaxis vs. Children Receiving monoclonal RSV IVIG prop vs. children receiving none”, Lois A. Nelson, MD, Medical College of Ohio

“The Burden of Respiratory Syncytial Virus (RSV): A Study of Child and Family Distress and Adjustment During Hospitalization and Recovery”, Multi-center, principle investigator, Mark Sorrentino, MD, MS

“Synagis Compliance and Satisfaction Survey”, Diane Langkamp, MD, MPH, Children’s Hospital, Columbus, Ohio

“Risk Factors for RSV Hospitalization”, Multi-center, primary investigator, Mark Sorrentino, MD, MS

PROFESSIONAL MEMBERSHIPS:

American College of Physician Executives
Society of Critical Care Medicine
American Academy of Pediatrics
American Medical Association
Sigma Xi, Associate Member

ACTIVITIES:

Corporate Chairperson, Cystic Fibrosis Foundation “Great Strides Event”, 2001. (\$20,000 raised)
Resident Contract Negotiation Committee, 1995
Pediatric Clerkship Representative, Chicago Medical School, 1992 – 1993
Freshman Orientation Advisor, Chicago Medical School, 1992

HONORS:

American Medical Association Physician’s Recognition Award, 2002-2005

Teaching Assistant, Department of Medicine
The Chicago Medical School, 1992

AFL-CIO Academic Scholarship, 1992

Teaching Assistant, Department of Microbiology
Loyola Marymount University, 1986-1987

Riordan Community Service Scholarship
Loyola Marymount University, 1986

Vice-Presidential Academic Scholarship
Loyola Marymount University, 1983-1987

Boy Scout of America: Eagle Scout, 1983

LANGUAGES:

Conversational Spanish